| Company type | Dxcover Limited |
|---|---|
| Industry | Natural Science and Engineering |
| Founded | 2016 |
| Founder | Matthew James Baker, David S. Palmer, Holly J. Butler, Mark Hegarty |
| Headquarters | , Scotland |
Area served | UK, EU, US |
| Products | Infrared Spectroscopy, Diagnostic Algorithm, Disease Prediction, Cancer Screening |
Number of employees | 24 |
| Website | www |
Dxcover Limited is a Scottish company which was founded in 16 May 2016.[1] It is based in Glasgow, UK. It combines novel hardwares with artificial intelligence algorithms. Patients' blood samples are analysed by scientists to detect the presence of diseases. It is a clinical stage liquid biopsy company[2] and uses artificial intelligence algorithms for early detection of cancers and other diseases to improve survival rates. Its marketplaces are located in the US, UK and EU.[3] The company aims to detect early stage (Stage I and Stage II) of cancers.[4][5]
History[edit]
The company was previously named as ClinSpec Diagnostics Limited between 16 May 2016 and 26 April 2021.[1] It is spun out from the University of Strathclyde, Glasgow. After that, it is rebranded as Dxcover Limited in 2021.[1]
Technology[edit]
Dxcover has developed 'Drop, Dry, Detect' technology which technically detects and works in minutes to detect signs of cancer using artificial intelligence trained model.
Panoramic platform is a multi-omic spectral analysis (MOSA) technology[6] for various cancers which are brain, advanced adenoma, colorectal, and lung cancer. This technology analyses the signals that were missed by traditional cancer detection methods.[7]
For brain tumors, there is no biomarker test available. The test algorithm makes use of the complete biological profile of the patient's serum sample rather than concentrating on a single biomarker for illness. Results are accessible in minutes, and no specialized sample preparation is needed.[8]
Funding[edit]
Based on research conducted at Strathclyde University, Dxcover Limited has raised over £10 million for its technology that enables the early diagnosis of numerous malignancies.[9]
Existing investors lead by Eos Advisory LLP contributed £7.5 million in Series A funding, with further contributions from the University of Strathclyde, Mercia Fund Management, Scottish Enterprise, Social Investment Scotland Ventures, and Norcliffe Capital. As Dxcover continues to expand its U.S. network, Boston-based life science investor Mark Bamforth of Thairm Bio also joined the round.[9]
The European Innovation Council also awarded the firm a £2.2 million grant.[9]
References[edit]
- ^ a b c "DXCOVER LIMITED overview - Find and update company information - GOV.UK". find-and-update.company-information.service.gov.uk. Retrieved 2024-06-06.
- ^ Cameron, James M.; Sala, Alexandra; Antoniou, Georgios; Brennan, Paul M.; Butler, Holly J.; Conn, Justin J. A.; Connal, Siobhan; Curran, Tom; Hegarty, Mark G.; McHardy, Rose G.; Orringer, Daniel; Palmer, David S.; Smith, Benjamin R.; Baker, Matthew J. (2023-11-09). "A spectroscopic liquid biopsy for the earlier detection of multiple cancer types". British Journal of Cancer. 129 (10): 1658–1666. doi:10.1038/s41416-023-02423-7. ISSN 0007-0920. PMC 10645969. PMID 37717120.
- ^ "Dxcover Early Cancer Detection Platform Founder & CEO Professor Matt Baker Featured Panelist at Global EIE24 Meeting". Yahoo Finance (in German). 2024-05-13. Retrieved 2024-06-06.
- ^ "Dxcover Limited". Scientist.com. Retrieved 2024-06-07.
- ^ Nicolson, Kirsty (2022-06-28). "Dxcover". Bellrock Technology. Retrieved 2024-06-07.
- ^ "Dxcover Limited: Dxcover Early Cancer Detection Platform Founder & CEO Professor Matt Baker Featured Panelist at Global EIE24 Meeting". FinanzNachrichten.de (in German). Retrieved 2024-06-07.
- ^ "Dxcover Early Cancer Detection Platform Founder & CEO Professor Matt Baker Featured Panelist at Global EIE24 Meeting". Yahoo Finance (in German). 2024-05-13. Retrieved 2024-06-07.
- ^ Group, Scottish Health Technologies (2021-10-29). "Dxcover™ brain cancer liquid biopsy test for early brain cancer detection in primary care". Scottish Health Technologies Group. Retrieved 2024-06-07.
- ^ a b c "Dxcover raises £10M to develop pioneering liquid biopsy platform for early-stage cancers | University of Strathclyde". www.strath.ac.uk. Retrieved 2024-06-07.